DAMORA THERAPEUTICS INC (DMRA)

What DAMORA THERAPEUTICS INC does

Damora Therapeutics is a biopharmaceutical company developing therapies for hematologic disorders, specifically targeting myeloproliferative neoplasms (MPNs). The company was created through an acquisition of Pre-Acquisition Damora in November 2025 and obtained a portfolio of three preclinical antibody product candidates (DMR-001, DMR-002, and DMR-003) designed to target mutant calreticulin (mutCALR) through a licensing option agreement with Paragon Therapeutics. The candidates employ distinct antibody mechanisms—including an Fc-null antibody and an afucosylated antibody—with potential to address the full spectrum of mutCALR-driven MPNs.

Fundamentals

• Price$30.78 as of 2026-07-09 close
• Market cap$1.9B as of 2026-07-10
• 1-year return+7.9% as of 2026-07-09 close
• ROE-123.1% as of 2026-07-10
• Debt / equity0.00 as of 2026-07-10
• Beta-4.33 as of 2026-07-10

Ask why DMRA looks like this →

Key risks (from latest filing)

["Preclinical-stage portfolio with no human-administered products or approvals; all candidates remain in research phase with uncertain development timelines and no guarantee of clinical or regulatory success","Substantial dependence on DMR-001 and reliance on Paragon Therapeutics for research execution and IP licensing; loss of or inability to maintain these collaborations would materially harm the business","Significant capital requirements to fund future development and commercialization; inability to raise necessary funding on acceptable terms could force reduction or elimination of research programs"]

See DMRA's biggest risks from its latest 10-Q →